Knight Therapeutics Inc logo

GUD - Knight Therapeutics Inc Share Price

C$6.85 -0.1  -1.0%

Last Trade - 04/08/20

Sector
Healthcare
Size
Mid Cap
Market Cap £515.7m
Enterprise Value £301.4m
Revenue £51.9m
Position in Universe 256th / 2677
Bullish
Bearish
Unlock GUD Revenue
Momentum
Relative Strength (%)
1m -5.84%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -22.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.37 1.04 5.94 8.63 12.5 47.5 214.5 240 +164.7%
+1,137 -56.1 -15.4 +28.5 +18.6 -73.6 +115.4
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Knight Therapeutics Inc revenues increased from C$3M to C$45.8M. Net loss totaled C$1.7M vs. income of C$5.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net loss reflects EFVI decrease from C$4.3M (income) to C$7.1M (expense), Selling and marketing increase from C$847K to C$10.1M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

GUD Revenue Unlock GUD Revenue

Net Income

GUD Net Income Unlock GUD Revenue

Normalised EPS

GUD Normalised EPS Unlock GUD Revenue

PE Ratio Range

GUD PE Ratio Range Unlock GUD Revenue

Dividend Yield Range

GUD Dividend Yield Range Unlock GUD Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
GUD EPS Forecasts Unlock GUD Revenue
Profile Summary

Knight Therapeutics Inc is a Canada-based specialty pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices. The Company’s products are ILUVIEN Fluocinolone acentonid, Nerlynx Neratinib Tablets, Burinex Bumetanide, Probuphine Buprenorphine implant and Movantik Naloxegol.

Directors
Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated January 1, 2015
Public Since February 28, 2014
No. of Shareholders: n/a
No. of Employees: 719
Sector Healthcare
Industry Pharmaceuticals
Index S&P/TSX Composite , S&P - Tse 300 Capped ,
Exchange Toronto Stock Exchange
Shares in Issue 130,938,418
Free Float (0.0%)
Eligible for
ISAs
SIPPs
GUD Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for GUD
Upcoming Events for GUD
Frequently Asked Questions for Knight Therapeutics Inc
What is the Knight Therapeutics Inc share price?

As of 04/08/20, shares in Knight Therapeutics Inc are trading at C$6.85, giving the company a market capitalisation of £515.7m. This share price information is delayed by 15 minutes.

How has the Knight Therapeutics Inc share price performed this year?

Shares in Knight Therapeutics Inc are currently trading at C$6.85 and the price has moved by -9.03% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Knight Therapeutics Inc price has moved by -9.14% over the past year.

What are the analyst and broker recommendations for Knight Therapeutics Inc?

Of the analysts with advisory recommendations for Knight Therapeutics Inc, there are there are currently 1 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Knight Therapeutics Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Knight Therapeutics Inc next release its financial results?

Knight Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Knight Therapeutics Inc dividend yield?

Knight Therapeutics Inc does not currently pay a dividend.

Does Knight Therapeutics Inc pay a dividend?

Knight Therapeutics Inc does not currently pay a dividend.

When does Knight Therapeutics Inc next pay dividends?

Knight Therapeutics Inc does not currently pay a dividend.

How do I buy Knight Therapeutics Inc shares?

To buy shares in Knight Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Knight Therapeutics Inc?

Shares in Knight Therapeutics Inc are currently trading at C$6.85, giving the company a market capitalisation of £515.7m.

Where are Knight Therapeutics Inc shares listed? Where are Knight Therapeutics Inc shares listed?

Here are the trading details for Knight Therapeutics Inc:

Country of listing: Canada
Exchange: TOR
Ticker Symbol: GUD
What kind of share is Knight Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Knight Therapeutics Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Knight Therapeutics Inc share price forecast 2020?

Shares in Knight Therapeutics Inc are currently priced at C$6.85. At that level they are trading at 30.36% discount to the analyst consensus target price of 0.00.

Analysts covering Knight Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of 0.052 for the next financial year.

How can I tell whether the Knight Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Knight Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been -4.23%. At the current price of C$6.85, shares in Knight Therapeutics Inc are trading at -6.66% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Knight Therapeutics Inc PE Ratio?

The Knight Therapeutics Inc PE ratio based on its reported earnings over the past 12 months is 62.53. The shares are currently trading at C$6.85.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Knight Therapeutics Inc?

Knight Therapeutics Inc's management team is headed by:

James Gale - CHM
Jonathan Goodman - CEO
Meir Jakobsohn - DRC
Robert Lande - IND
Samira Sakhia - PRE
Sylvie Tendler - IND
Amal Khouri - VBD
Nancy Harrison - IND
Michael Tremblay - IND
Jody Engel - OTH
Arvind Utchanah - OTH
Who are the major shareholders of Knight Therapeutics Inc?

Here are the top five shareholders of Knight Therapeutics Inc based on the size of their shareholding:

Long Zone Holdings, Inc. Corporation
Percentage owned: 16.52% (21.6m shares)
QV Investors Inc. Investment Advisor
Percentage owned: 4.1% (5.37m shares)
EdgePoint Investment Group Inc. Investment Advisor
Percentage owned: 2.29% (2.99m shares)
GWL Investment Management Ltd. Investment Advisor
Percentage owned: 2.11% (2.77m shares)
Mawer Investment Management Ltd. Investment Advisor
Percentage owned: 2.01% (2.63m shares)
Similar to GUD
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.